Carolina Reduzzi, Chief Operating Officer and Treasurer – Non-profit at Precision Medicine Action for Cancer (PMAC), shared a post on LinkedIn:
“Excited to share our review article published in Cancer, American Cancer Society Journals!
While ctDNA analysis has revolutionized precision management in metastatic disease, translating these liquid biopsy approaches to early breast cancer presents unique biological and analytical challenges.
In this review led by Serena Di Cosimo and Valentina Appierto we dive into:
- Shedding and Kinetics
- Technical Considerations
- Clinical Applications
- Clinical Trial Landscape.”
Title: Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps
Authors: Serena Di Cosimo, Valentina Appierto, Carolina Reduzzi, Loris De Cecco, Carmine Valenza, Lorenzo Gerratana, Elisa Agostinetto, Antonio Llombart-Cussac, Michail Ignatiadis, Javier Cortes, Massimo Cristofanilli, Nicola Fusco, Giuseppe Curigliano, Giancarlo Pruneri
Read the full article.
You can also explore:
RxPONDER Analysis: Ovarian Reserve May Refine Chemotherapy Decisions in HR-Positive Breast Cancer